168 related articles for article (PubMed ID: 24175816)
21. Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival.
Orditura M; Romano C; De Vita F; Galizia G; Lieto E; Infusino S; De Cataldis G; Catalano G
Cancer Immunol Immunother; 2000 Dec; 49(10):530-6. PubMed ID: 11129323
[TBL] [Abstract][Full Text] [Related]
22. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
23. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.
Haghgoo SM; Khosravi A; Mortaz E; Pourabdollah-Toutkaboni M; Seifi S; Sabour S; Allameh A
Clin Biochem; 2017 Apr; 50(6):293-300. PubMed ID: 27923629
[TBL] [Abstract][Full Text] [Related]
25. IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients.
Wang W; Huang L; Jin JY; Jolly S; Zang Y; Wu H; Yan L; Pi W; Li L; Mellor AL; Kong FS
Cancer Res; 2018 Feb; 78(3):809-816. PubMed ID: 29118088
[TBL] [Abstract][Full Text] [Related]
26. The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients.
Fidler MJ; Fhied CL; Roder J; Basu S; Sayidine S; Fughhi I; Pool M; Batus M; Bonomi P; Borgia JA
BMC Cancer; 2018 Mar; 18(1):310. PubMed ID: 29558888
[TBL] [Abstract][Full Text] [Related]
27. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.
Nisman B; Biran H; Heching N; Barak V; Ramu N; Nemirovsky I; Peretz T
Br J Cancer; 2008 Jan; 98(1):77-9. PubMed ID: 18087272
[TBL] [Abstract][Full Text] [Related]
28. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer.
Sirera R; Bremnes RM; Cabrera A; Jantus-Lewintre E; Sanmartín E; Blasco A; Del Pozo N; Rosell R; Guijarro R; Galbis J; Sánchez JJ; Camps C
J Thorac Oncol; 2011 Feb; 6(2):286-90. PubMed ID: 21252717
[TBL] [Abstract][Full Text] [Related]
29. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
30. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
31. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of metastasis to the highest mediastinal lymph node in nonsmall cell lung cancer.
Sakao Y; Miyamoto H; Yamazaki A; Oh T; Fukai R; Shiomi K; Saito Y
Ann Thorac Surg; 2006 Jan; 81(1):292-7. PubMed ID: 16368383
[TBL] [Abstract][Full Text] [Related]
33. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
[TBL] [Abstract][Full Text] [Related]
34. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer.
Yan P; Han Y; Tong A; Liu J; Wang X; Liu C
Biosci Rep; 2021 Aug; 41(8):. PubMed ID: 34286335
[TBL] [Abstract][Full Text] [Related]
36. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
[TBL] [Abstract][Full Text] [Related]
37. The serum level of CC chemokine ligand 18 correlates with the prognosis of non-small cell lung cancer.
Huang H; Li J; Hu WJ; Chen C; Luo HQ; Tang XD; Zhou KY; Zhong WT; Li XY
Int J Biol Markers; 2019 Jun; 34(2):156-162. PubMed ID: 31046524
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of serum vascular endothelial growth factor and Angiopoietin-2 in patients with lung cancer.
Akın Kabalak P; Çiledağ A; Demir N; Çelik G; Yüksel C; Köycü G; Gökmen Öztuna D; Taner A; Kaya A; Kutlay H; Numanoğlu N; Savaş İ
Tuberk Toraks; 2015 Jun; 63(2):71-7. PubMed ID: 26167963
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
40. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
